Navigo and Mannin Ink Deal to Develop COVID-19 Treatment

German biotech Navigo Proteins is teaming up with the German subsidiary of Ontario, Canada-based Mannin Research to develop Mannin’s investigational recombinant protein as a treatment for patients with COVID-19.

Specifically, the protein is designed to activate an enzyme that plays a role in blood vessel formation and maintenance which may improve patient outcomes with severe infections including COVID-19.

Navigo will be providing Mannin with its technology for purification of proteins for use in manufacturing the potential final drug product.

The financial terms of the deal were not disclosed.